查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
旋磨设备市场——增长、趋势和预测 (2023-2028)
市场调查报告书
商品编码
1189875

旋磨设备市场——增长、趋势和预测 (2023-2028)

Atherectomy Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 121 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，旋磨设备市场预计将以 6.03% 左右的复合年增长率增长。

与许多其他市场一样，市场也受到了 COVID-19 大流行的影响。 各种心血管手术和非必要治疗已被推迟。 2022 年 3 月，发表在《胸外科年鑑》上的研究结果分析了 717,103 名成人心臟手术患者和超过 2000 万名 COVID-19 患者。据说有所减少。 中大西洋地区受最初 COVID-19 激增的影响最大，总体病例下降 69.7%，部分病例下降 80.0%。 在大西洋中部和新英格兰地区，观察到的孤立冠状动脉搭桥手术的死亡率与 COVID 之前相比显着增加了 1.48 倍（增加 148%）。 在最初的 COVID-19 激增之后，全国心臟手术病例数没有恢復到基线水平，表明与 COVID-19 相关的心臟手术患者数量不足。 动脉粥样硬化斑块切除术是一种清除心臟阻塞动脉的手术。 心臟手术还将包括粥样斑块切除术。 因此，整个市场都受到了影响。 因此，在全球范围内，随着 COVID-19 限制的放宽，市场有望在几年内获得牵引力并全面反弹。

粥样斑块旋切术设备市场的主要驱动因素是人们越来越偏爱微创手术。 扩大微创手术的研究也是推动市场增长的因素之一。 2021 年 10 月，经皮冠状动脉介入治疗 (PCI) 的持续进步促使外科医生降低外科血运重建手术的侵入性，导致微创心臟手术 (MICS) 技术的发展。在过去几十年中得到了广泛扩展，根据发表在 Elsevier Journal 上的一项研究。 MICS 的主要目标是避免胸骨切开术、减少术后输血、减少通气时间、减少重症监护和住院时间、减少术后疼痛以及促进恢復正常活动。 由于这些优势，MICS 的采用正在增加，市场有望增长。

此外，持续的产品开发和商业化有望推动市场增长。 2021 年 11 月，皇家飞利浦将在美国奥兰多推出包括 Nexcimerlaser 系统在内的外周和冠状动脉应用。 新的飞利浦激光系统 -Nexcimer - 为冠状动脉和外周动脉粥样硬化斑块切除术和导线拔除手术提供即插即用的简单性。 该系统是唯一接受用于 ISR 粥样斑块切除术的临床数据 I 级导管的系统，并且还与导线提取兼容（去除心臟周围的起搏器和除颤器导线）。

在当前医疗、医疗费用和保险制度改革的趋势下，患者及其护理人员必须将支付方和提供方联繫起来，以应对飙升的医疗费用。 报销和保险范围改革将增加在保险范围内选择治疗的机会。 因此，增加赎回将增加未来一段时间的市场增长。 2022 年，医疗保险和医疗补助服务中心 (CMS) 将增加外周血管内碎石术 (IVL) 手术的报销。 涉及血运重建的手术，不包括血管内、开放或经皮、腿部动脉、胫骨/腓骨；包括在同一血管内进行的血管成形术和血管内碎石术（CPT 代码：C9764）您将收到 10258 美元。 同样，涉及血运重建、血管内治疗、开放或经皮手术、除胫骨/腓骨外的下肢动脉的手术；如果包括内部血管成形术，将支付 16,402 美元（CPT 代码：C9765）。 此外，非胫骨/腓骨下肢动脉（涉及血管内、开放或经皮再灌注的过程）、血管内碎石术和腔内支架置入术（多个）和粥样斑块切除术（同一血管内的血管成形术）（CPT 代码：C9767），您将支付 16,402 美元。 因此，上述所有因素预计将在预测期内提振市场。

但是，严格的监管情景可能会在预测期内抑制市场增长。

主要市场趋势

在预测期内，定向斑块切除术部分将在调查的市场中占有重要的市场份额

在预测期内，定向旋磨术预计将比其他产品增长更多，因为它具有某些优势，例如降低治疗成本和提高效率。 越来越多地采用微创动脉粥样硬化斑块切除术可能会增加对斑块切除术设备的需求。 根据 Krishna J. Rocha-Singh 等人于 2021 年 6 月发表的一项研究，在药物涂层球囊 (DCB) 血管成形术之前通过定向粥样斑块切除术 (DA) 去除斑块与有症状的严重钙化有关。它被发现是股腘动脉疾病患者临时支架率低的安全有效治疗方法。 因此，此类研究有望进一步促进 DA 系统的使用，从而有望推动所调查领域的增长。

主要市场参与者的战略举措，如产品发布、併购和合作伙伴关係，预计也将有助于市场增长。 例如，2021 年 8 月，美敦力 (Medtronic) 向 USFDA 提交了一份申请，要求批准 TurboHawk Plus 定向斑块切除术系统，这是一种较旧且已基本淘汰的斑块切除术设备的更新版本。 该装置有助于在外周动脉疾病 (PAD) 干预期间增加粥样斑块切除术。 此外，2021 年 11 月，Avinger Inc .获得了美国 FDA 的 510(k) 许可，用于其 Pantherisimage 引导的粥样斑块切除术系统的新临床适应症。 该批准允许该公司直接销售 Pantheris 用于治疗下肢动脉支架内再狭窄（ ISR ）。

因此，由于手术和产品创新的数量不断增加，因此在本研究的预测期内，定向粥样斑块切除术系统部分有望实现增长。

北美将占据很大的市场份额，预计在预测期内也会如此

预计北美将占据很大的市场份额。 旋磨系统的报销增加，医护人员采用旋磨系统，大量外周动脉疾病和冠状动脉疾病患者，临床试验（为了评估

根据疾病预防控制中心 2022 年 2 月的更新，无论性别、种族或民族如何，心脏病都是导緻美国死亡的主要原因，而冠心病是最常见的心脏病类型。(CHD) 或冠心病动脉疾病，其中冠状动脉变窄和在其壁中形成胆固醇堵塞可导致中风和心脏病发作。 因此，由于心脏病患病率上升，该地区对斑块切除手术的需求预计将增加，预计这将在预测期内推动监测市场的增长。

合适的报销场景和大量的FDA批准的设备是这一优势的主要原因。 例如，2021 年 10 月，BD（Becton, Dickinson & Company）宣布已获得美国 FDA 的 510(k) 许可，用于扩大 Rotarex Atherectomy 系统的适应症。 此外，2021 年 11 月，皇家飞利浦宣布在北美首次亮相新的外周和冠状动脉应用，包括 IntraSight Mobile 系统和 Nexcimer 激光系统。

因此，上述所有因素预计将在预测期内提振该地区的市场。

竞争格局

由于许多跨国公司的存在，旋磨术市场竞争相当激烈。 例如，Abbott Laboratories、B. Braun SE、Boston Scientific、CR Bard、Cardinal Health Inc、Koninklijke Philips NV、Medtronic PLC 和 Terumo Corporation 在全球范围内提供产品。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 持续的产品开发和商业化
    • 成熟市场中有利的医疗报销方案
    • 对微创手术的需求不断增长
  • 市场製约因素
    • 严格的监管场景
    • 缺乏训练有素的外科医生
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按产品分类
    • 定向旋磨系统
    • 眼眶运动系统
    • 光消融（激光）旋磨系统
    • 旋磨系统
  • 通过使用
    • 外周血管
    • 心血管
    • 神经血管
  • 最终用户
    • 医院、手术中心
    • 门诊中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • B. Braun SE
    • Boston Scientific Corporation
    • Becton, Dickinson and Company
    • Cardinal Health Inc.
    • Koninklijke Philips NV
    • Medtronic
    • RA Medical Systems
    • Terumo Corporation
    • Cardiovascular Systems Inc.
    • Biomerics LLC
    • AngioDynamics Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 60425

The atherectomy devices market is expected to record a CAGR of about 6.03% during the forecast period 2022-2027.

Like many other markets, the market was impacted by the COVID-19 pandemic. Various cardiovascular procedures and non-essential treatments were postponed. In March 2022, a research study was published in the Annals of Thoracic Surgery, which analyzed 717,103 adult cardiac surgery patients and more than 20 million COVID-19 patients stated that there was a 52.7% reduction in adult cardiac surgery volume and a 65.5% reduction in elective cases. The Mid-Atlantic region was most affected by the first COVID-19 surge, with a 69.7% reduction in overall case volume and an 80.0% reduction in elective cases. In the Mid-Atlantic and New England regions, the observed-to-expected mortality for isolated coronary bypass increased as much as 1.48 times (148% increase) pre-COVID rates. After the first COVID-19 surge, nationwide cardiac surgical case volumes did not return to baseline, indicating a COVID-19-associated deficit in cardiac surgery patients. Atherectomy is a procedure used to clear out clogged heart arteries. The cardiac surgeries would also include atherectomy surgeries. Hence, the market was affected across the globe. Hence, with the easing of COVID-19 restrictions, worldwide, the market gained traction and is expected to bounce back to its full potential over the years.

The market for atherectomy devices is majorly driven by the increasing preference for minimally invasive surgeries. Research studies about the expansion of minimally invasive surgeries are another factor that drives the market growth. In October 2021, a research study was published in Elsevier Journal, stating that continuous progress in percutaneous coronary intervention (PCI) has inspired surgeons to reduce the invasiveness of surgical revascularization techniques, resulting in the development of minimally invasive cardiac surgery (MICS) procedures, which have widely expanded over the past couple of decades. The main goals of MICS are to avert any form of sternotomy, reduce postoperative blood product transfusion, shorten ventilation times, reduce intensive care and hospital stays, diminish postoperative pain, and accelerate the return to normal activities. Hence, due to such advantages of MICS, there will be growth in the adoption of such surgeries which would increase the market growth.

Additionally, continuous product development and commercialization are expected to propel the growth of the market. In November 2021, Royal Philips launched peripheral and coronary artery applications, including the Nexcimerlaser system in Orlando, United States. The new Philips Laser System - Nexcimer- offers plug-and-play simplicity for coronary and peripheral atherectomy and lead extraction procedures. It is the only system compatible with catheters with Level I clinical data for ISR atherectomy and that can also support lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart).

In the current trend of healthcare, reimbursement, and coverage reform, payer and provider consolidation for escalating healthcare costs are essential for patients and their caregivers. ​Reimbursement and coverage reform enhances the chances of opting for the treatment if it is covered. Hence, increasing reimbursement would increase the market growth in the upcoming period. In 2022, the Centers for Medicare and Medicaid Services (CMS), has increased reimbursement for peripheral intravascular lithotripsy (IVL) procedures. Procedure including revascularization, endovascular, open or percutaneous, lower extremity arteries, except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel (s) (CPT code: C9764) will receive USD 10,258. Similarly, a procedure including revascularization, endovascular, open or percutaneous, lower extremity arteries, except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessels, (CPT code: C9765) will receive USD 16,402. Furthermore, processes including revascularization, endovascular, open or percutaneous, lower extremity arteries), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, including angioplasty within the same vessels, when performed (CPT code: C9767) will receive USD 16,402. Thus, all the above-mentioned factors are expected to boost the market over the forecast period.

However, the stringent regulatory scenarios may restrain the market growth over the forecast period.

Key Market Trends

Directional Atherectomy Segment Holds a Significant Market Share in the Studied Market Over the Forecast Period

The directional atherectomy segment of the market is expected to witness significant growth in the forecast period over other products as it offers certain advantages such as low treatment cost, improved efficiency, etc. The increasing adoption of minimally invasive atherectomy procedures may boost the demand for atherectomy devices. According to a research study published by Krishna J. Rocha-Singh et. al., in June 2021, plaque removal with directional atherectomy (DA) before drug-coated balloon (DCB) angioplasty is a safe and effective treatment technique with a low provisional stent rate in patients with symptomatic severely calcified femoropopliteal artery disease. Thus, research studies like these are further expected to promote the usage of DA systems which is anticipated to fuel growth in the studied segment.

The strategic initiatives taken by key market players such as product launches, mergers and acquisitions, and partnerships are also expected to contribute to market growth. For instance, in August 2021, Medtronic submitted an application to the USFDA for the approval of the TurboHawk Plus Directional Atherectomy System, an updated version of its older and largely phased-out atherectomy device. This device will facilitate increased atherectomy procedures during Peripheral Arterial Disease (PAD) interventions. Additionally, in November 2021, Avinger Inc. received 510(k) approval from United States FDA for the Pantherisimage-guided atherectomy system's new clinical indication. This clearance allows the company to directly market Pantheris forthe treatment of in-stent restenosis (ISR) in the lower extremity arteries.

Therefore, overall, with the growing number of surgeries, and product innovation, the directional atherectomy systems segment is expected to grow during the forecast period of the study.

North America Holds a Significant Share in the Market and Expected to do Same during the Forecast Period

North America is expected to hold a significant share of the market. Factors such as increasing availability of reimbursements for atherectomy systems, adoption of atherectomy systems among medical professionals, the large patient population of peripheral and coronary artery diseases, and an increasing number of clinical trials (that aim to evaluate the therapeutic efficacy of atherectomy systems in specific disease treatment) are driving the growth of the North American atherectomy devices market.

According to the February 2022 update of the CDC, in United States, heart diseases are the leading cause of death irrespective of gender, race, or ethnicity and the most common type of heart disease is coronary heart disease (CHD) or coronary artery disease in which coronary arteries become too narrow or cholesterol blockages develop in the walls, leading to stroke or heart attack. Thus, due to the rising prevalence of heart diseases, the demand for atherectomy procedures is expected to increase in the region which is anticipated to fuel growth in the studied market over the forecast period.

A suitable reimbursement scenario and a high number of FDA-approved devices are the key reasons for this dominance. For instance, in October 2021, BD (Becton, Dickinson and Company) announced it has received 510(k) clearance for expanded indications from the U.S. FDA for the Rotarex Atherectomy System. Additionally, in November 2021, Royal Philips announced the North American debut of new peripheral and coronary artery applications, including the IntraSight Mobile system and the Nexcimer laser system.

Thus, all above mentioned factors expected to boost the market in the region over the forecast period.

Competitive Landscape

The atherectomy devices market is moderately competitive, with the presence of many global players. For instance, Abbott Laboratories, B. Braun SE, Boston Scientific, CR Bard, Cardinal Health Inc., Koninklijke Philips NV, Medtronic PLC, Terumo Corporation, etc., are offering their products across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Continuous Product Development and Commercialization
    • 4.2.2 Favourable Medical Reimbursement Scenario in Mature Markets
    • 4.2.3 Growing Demand for Minimally Invasive Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Lack of Well-trained Surgeons
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product
    • 5.1.1 Directional Atherectomy Systems
    • 5.1.2 Orbital Atherectomy Systems
    • 5.1.3 Photo-ablative (Laser) Atherectomy Systems
    • 5.1.4 Rotational Atherectomy Systems
  • 5.2 By Application
    • 5.2.1 Peripheral Vascular Applications
    • 5.2.2 Cardiovascular Applications
    • 5.2.3 Neurovascular Applications
  • 5.3 By End User
    • 5.3.1 Hospitals and Surgical Centers
    • 5.3.2 Ambulatory Care Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 B. Braun SE
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Cardinal Health Inc.
    • 6.1.6 Koninklijke Philips NV
    • 6.1.7 Medtronic
    • 6.1.8 RA Medical Systems
    • 6.1.9 Terumo Corporation
    • 6.1.10 Cardiovascular Systems Inc.
    • 6.1.11 Biomerics LLC
    • 6.1.12 AngioDynamics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS